SRH Wald-Klinikum Gera

Tumour stage distribution and survival of malignant melanoma in Germany 2002-2011 (2016) Schoffer O, Schuelein S, Arand G, Arnholdt H, Baaske D, Bargou RC, Becker N, et al. Journal article A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival (2015) Ugurel S, Loquai C, Kaehler K, Hassel J, Berking C, Zimmer L, Haubitz I, et al. Journal article Recurrent Mutations within the Amino-Terminal Region of ?-Catenin Are Probable Key Molecular Driver Events in Sinonasal Hemangiopericytoma (2015) Haller F, Bieg M, Moskalev E, Barthelmeß S, Geddert H, Boltze C, Diessl N, et al. Journal article Incidence of bleeding in 8172 percutaneous ultrasound-guided intraabdominal diagnostic and therapeutic interventions - results of the prospective multicenter DEGUM interventional ultrasound study (PIUS study) (2015) Strobel D, Bernatik T, Blank W, Will U, Reichel A, Wuestner M, Keim V, et al. Journal article Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial (2014) Von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, et al. Journal article Solitary fibrous tumors/hemangiopericytomas with different variants of the NAB2-STAT6 gene fusion are characterized by specific histomorphology and distinct clinicopathological features (2014) Barthelmeß S, Geddert H, Boltze C, Moskalev E, Bieg M, Sirbu H, Brors B, et al. Journal article Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing (2014) Moskalev E, Frohnauer J, Merkelbach-Bruse S, Schildhaus HU, Dimmler A, Schubert T, Boltze C, et al. Journal article Phenotypical and molecular distinctness of sinonasal haemangiopericytoma compared to solitary fibrous tumour of the sinonasal tract (2014) Agaimy A, Barthelmeß S, Geddert H, Boltze C, Moskalev E, Koch M, Wiemann S, et al. Journal article PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer (2014) Loibl S, Von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, Zahm DM, et al. Journal article Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma" (2013) Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenborn T, Dill D, et al. Journal article